A novel microbial-derived peptide therapeutic vaccine (EO2463) as monotherapy and in combination with lenalidomide and rituximab, for treatment of patients with indolent non-Hodgkin lymphoma (SIDNEY).

Pier Luigi Zinzani (1) , Stephen M. Ansell (2) , Francesc Bosch (3) , Jonathan W. Friedberg , Jean Pierre Marolleau (4, 5) , Luca Arcaini (6, 7) , Ramon Garcia-Sanz (8) , Ajay K. Gopal , Carlos Grande (9) , Reid Merryman (10) , Antonio Pinto , Stephen D. Smith (11) , Jose Caetano Villasboas , Danielle Wallace , Jan Fagerberg , Joao Magalhaes (12) , Philippe Armand (10)

1 University of Bologna/Università di Bologna
2 Mayo Clinic [Rochester]
3 Vall d'Hebron University Hospital [Barcelona]
4 CHU Amiens-Picardie
5 HEMATIM - HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666
6 UNIPV - Università degli Studi di Pavia = University of Pavia
7 Fondazione IRCCS Policlinico San Matteo [Pavia]
8 Hospital Universitario de Salamanca
9 SINTEF Materials and Chemistry
10 Dana-Farber Cancer Institute [Boston]
11 University of Washington [Seattle]
12 NOVA-LINCS - NOVA Laboratory for Computer Science and Informatics

Domaines: Sciences du Vivant [q-bio]; Médecine humaine et pathologie

Pier Luigi Zinzani, Stephen M. Ansell, Francesc Bosch, Jonathan W. Friedberg, Jean Pierre Marolleau, et al.. A novel microbial-derived peptide therapeutic vaccine (EO2463) as monotherapy and in combination with lenalidomide and rituximab, for treatment of patients with indolent non-Hodgkin lymphoma (SIDNEY).. Journal of Clinical Oncology, 2022, 40 (16, S). ⟨hal-03837958⟩